)
)
Graphite Bio Investor Relations Material
Latest events
M&A Announcement
Graphite Bio
Access the full event backlog
Slides, Transcripts, and Reports from 11,000+ public companies
Latest reports from Graphite Bio Inc
Access all reports
Graphite Bio, Inc., a clinical-stage gene editing company, engages in developing therapies for diseases, primarily focused on therapies for serious and life-threatening diseases, in the United States. The company develops TALEN gene editing system for the treatment of various human diseases, including cancers. It is also involved in developing electroporation technology for drug and gene delivery.
Latest articles
)
Under the Hood: AutoZone's Blueprint for Retail Excellence
An in-depth look at the largest aftermarket auto parts retailer in the U.S., its philosophy, and masterful capital allocation.
19 Dec 2024
)
Lessons from Gautam Baid: Mastering Simplicity and Compounding
Gautam Baid's journey of compounding wisdom, investing simplicity, and lifelong learning – insights to transform your financial and personal growth.
13 Dec 2024
)
Rocket Lab: Breaking Ground in Space
Rocket Lab has been one of the pioneers in the commercial aerospace industry, with numerous satellite launches and space system applications.
9 Dec 2024
Ticker symbol
GRPH
Country
🇺🇸 United States